Prosecution Insights
Last updated: November 17, 2026

Cardiff Oncology Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Analysis

Cardiff Oncology Inc. is managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions. These actions are distributed among 4 distinct examiners, which means that each examiner is currently reviewing a single case. The prosecution activity is also spread across 4 distinct art units, indicating a high level of technical or procedural variety within the company's active filings.

BRAUN, MADELINE E is the busiest examiner for the portfolio, with 1 pending office action. Given that there are 4 distinct examiners for the 4 pending actions, the workload is evenly distributed across the individuals involved. The fact that there are 4 distinct art units for 4 pending actions is significant: every active case is being reviewed in a different specialized division of the patent office. For a practitioner, this requires managing four different examiner relationships and navigating the specific guidelines of four separate art units simultaneously.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (75%)
0
Medium (0%)
1
Easy (25%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (25%)
Multi-statute (no §101)3 (75%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BRAUN, MADELINE E 1 68.6% +24.8%
MCKOY, QUINCY ANDRE 1 69.2% +39.4%
JOHNSON, CHRISTOPHER LINDSAY 1 48.6% +79.2%
MOU, LIYUAN 1 43.8% +59.9%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18710027 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS BRAUN, MADELINE E —
18554158 CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS MCKOY, QUINCY ANDRE —
17433440 ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION MOU, LIYUAN —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17923803 METHODS OF MONITORING KRAS MUTATIONS JOHNSON, CHRISTOPHER LINDSAY 13d
18710027 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS BRAUN, MADELINE E —
18554158 CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS MCKOY, QUINCY ANDRE —
17433440 ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION MOU, LIYUAN —

Top Art Units

Art UnitApps
1624 1
1626 1
1691 1
1628 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18710027 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS BRAUN, MADELINE E 1624 §103§112 Non-Final OA — Pending May 14, 2024
18554158 CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS MCKOY, QUINCY ANDRE 1626 §103§112 Non-Final OA — Pending Oct 05, 2023
17923803 METHODS OF MONITORING KRAS MUTATIONS JOHNSON, CHRISTOPHER LINDSAY 1691 §112 Non-Final OA 13d Pending Apr 28, 2023
17433440 ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION MOU, LIYUAN 1628 §103§112 Final Rejection — Pending Aug 24, 2021

Managing Cardiff Oncology Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Cardiff Oncology Inc. have?

Cardiff Oncology Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.

Which USPTO examiner handles the most Cardiff Oncology Inc. applications?

Madeline E Braun has the most, with 1 of Cardiff Oncology Inc.'s pending office actions.

What technology area are Cardiff Oncology Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month